Stopping ACE-inhibitors in COVID-19

Inclusion Criteria: * Female and male patients competent to make a decision * Proven and symptomatic SARS-CoV2 infection ≤ 5 days * Patient age ≥ 18 years * Provided written informed consent * Chronic (≥ 1 month) ACEI/ARB therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease * Stable hemodynamic conditions allowing to stop or continue treatment with ACEI/ARB (systolic blood pressure ≤180mmHg) Exclusion Criteria: * Women capable of bearing children as well as pregnant and breastfeeding women * Participant in another interventional trail * At screening visit, no oral medication intake possible * Advanced heart failure NYHA Stage III-IV * Left ventricular ejection fraction \<30% or NTproBNP ≥600pg/mL in case of clinical signs of heart failure * Acute coronary syndrome ≤ 3 months * Severe arterial hypertension (concomitant use of more than 4 different antihypertensive drug classes) * Acute respiratory distress syndrome with need for mechanical ventilation * Patients who at not capable of home blood pressure monitoring * Patients who cannot be switched to an alternative medication